Notably, increased CPT1A levels were also observed in SCC1 and Tu686 cells treated with either malonate or lonidamine (Figure S12, Supporting Information), suggesting that TCA cycle inhibition may induce enhanced CPT1A expression in HNSCC cells harboring mutant FAT1. This evidence concerns the gene FAT1 and head and neck squamous cell carcinoma.